Safety of Acupuncture in Patients Taking Newer Oral Anticoagulants: A Retrospective Chart Review Study
Table 2
General patient characteristics.
Group A (n = 28)
Group B (n = 145)
Group C (n = 143)
p value
Sex, n (%)
Male
14 (50.0)
78 (53.8)
64 (44.8)
0.308
Female
14 (50.0)
67 (46.2)
79 (55.2)
Age, years
73.14 ± 9.60
67.52 ± 11.44
62.60 ± 13.42
<0.001
Medical history, n ()
Atrial fibrillation
24 (85.7)
1 (0.7)
4 (2.7)
<0.001
Hypertension
13 (41.9)
96 (66.2)
72 (50.3)
0.005
Diabetes mellitus
8 (22.2)
58 (28.2)
31 (17.8)
0.048
Hyperlipidemia
5 (15.2)
53 (26.8)
31 (17.8)
0.071
NOAC therapy, n ()
Dabigatran
11 (39.3)
0
0
Rivaroxaban
2 (7.1)
0
0
Apixaban
15 (53.6)
0
0
Antiplatelet therapy, n (%)
Aspirin
1
50 (34.5)
0
Clopidogrel
1
35 (24.1)
0
Triflusal
0
7 (4.8)
0
Aspirin + clopidogrel
0
46 (31.7)
0
Aspirin + triflusal
0
7 (4.8)
0
The data are shown as the mean ± standard deviation or number (percentage). Group A includes patients taking an NOAC. Group B includes patients taking an antiplatelet agent. Group C includes the controls who were not taking an NOAC or antiplatelet agent. Analysis of variance used for age and the chi-squared test for categorical variables.
